Natco Pharma gets tentative US FDA nod for Erdafitinib generic

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.0%Reaction day

₹823.00

prior close

₹855.40

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+2.9%+1.1% vs market

Pharmaceuticals peers, median of 157sector+2.6%+1.5% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Smallcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.4

15m

-0.4

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.0+2.9+1.1+2.6+1.5

Next day

+2.4+3.7-1.3+2.6-0.2

+0.8+2.7-1.9+1.7-0.9

+0.2+2.3-2.1+1.2-1.0

+2.8+4.9-2.1+2.9-0.1

+3.0+5.4-2.4+3.6-0.5

+1.5+4.8-3.3+2.6-1.0

15d

+14.8+2.7+12.0-0.7+15.5

+16.0-1.7+17.7-2.7+18.7

+25.1-4.0+29.2-4.8+30.0

+36.0+9.0+27.0+4.0+32.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natco Pharma received tentative US FDA approval for Erdafitinib tablets (3mg, 4mg, 5mg), a generic of Janssen Biotech's Balversa. The drug treats adult patients with advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations. Erdafitinib had estimated US sales of about USD 60 million in the 12 months ending September 2025. Tentative approval means Natco can launch the generic in the US once patent hurdles are resolved.

Likely market impact

Positive for long-term US generic oncology revenue, but commercial launch depends on patent outcome. No immediate sales impact.